ACADIA Pharmaceuticals Valuation
| ACAD Stock | USD 25.13 0.57 2.22% |
At this time, the entity appears to be undervalued. ACADIA Pharmaceuticals owns a latest Real Value of $28.01 per share. The recent price of the entity is $25.13. Our model approximates the value of ACADIA Pharmaceuticals from examining the entity fundamentals such as shares outstanding of 169.18 M, and Return On Asset of 0.0511 as well as evaluating its technical indicators and probability of bankruptcy. Key fundamental drivers impacting ACADIA Pharmaceuticals' valuation include:
Price Book 4.7401 | Enterprise Value | Enterprise Value Ebitda 32.7847 | Price Sales 4.0602 | Forward PE 39.6825 |
Undervalued
Today
Please note that ACADIA Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of ACADIA Pharmaceuticals is based on 3 months time horizon. Increasing ACADIA Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the ACADIA stock is determined by what a typical buyer is willing to pay for full or partial control of ACADIA Pharmaceuticals. Since ACADIA Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of ACADIA Stock. However, ACADIA Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.13 | Real 28.01 | Target 31.05 | Hype 25.05 | Naive 25.13 |
The real value of ACADIA Stock, also known as its intrinsic value, is the underlying worth of ACADIA Pharmaceuticals Company, which is reflected in its stock price. It is based on ACADIA Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of ACADIA Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of ACADIA Pharmaceuticals helps investors to forecast how ACADIA stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ACADIA Pharmaceuticals more accurately as focusing exclusively on ACADIA Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use ACADIA Pharmaceuticals' intrinsic value based on its ongoing forecasts of ACADIA Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against ACADIA Pharmaceuticals' closest peers. If more than one evaluation category is relevant for ACADIA Pharmaceuticals we suggest using both methods to arrive at a better estimate.
ACADIA Pharmaceuticals Cash |
|
ACADIA Pharmaceuticals Total Value Analysis
ACADIA Pharmaceuticals is presently forecasted to have valuation of 3.56 B with market capitalization of 4.25 B, debt of 51.99 M, and cash on hands of 436.35 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the ACADIA Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.56 B | 4.25 B | 51.99 M | 436.35 M |
ACADIA Pharmaceuticals Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The book value of ACADIA Pharmaceuticals was presently reported as 5.42. The company last dividend was issued on the 30th of June 2010. Based on the key indicators related to ACADIA Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, ACADIA Pharmaceuticals is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in March.ACADIA Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ACADIA Pharmaceuticals has an asset utilization ratio of 80.64 percent. This indicates that the Company is making $0.81 for each dollar of assets. An increasing asset utilization means that ACADIA Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.ACADIA Pharmaceuticals Profitability Analysis
Based on ACADIA Pharmaceuticals' profitability indicators, ACADIA Pharmaceuticals is performing exceptionally good at this time. It has a great odds to showcase excellent profitability results in March. Profitability indicators assess ACADIA Pharmaceuticals' ability to earn profits and add value for shareholders.Net Income | First Reported 2002-12-31 | Previous Quarter 26.7 M | Current Value 71.8 M | Quarterly Volatility 36.7 M |
For ACADIA Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ACADIA Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ACADIA Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ACADIA Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ACADIA Pharmaceuticals over time as well as its relative position and ranking within its peers.
ACADIA Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of ACADIA Pharmaceuticals is estimated to be 0.198925 with future projections ranging from a low of 0.09 to a high of 0.2875. ACADIA Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at 1.52. Please be aware that the consensus of earnings estimates for ACADIA Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.ACADIA Pharmaceuticals Earnings Estimation Breakdown
The calculation of ACADIA Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of ACADIA Pharmaceuticals is estimated to be 0.198925 with the future projection ranging from a low of 0.09 to a high of 0.2875. Please be aware that this consensus of annual earnings estimates for ACADIA Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.09 Lowest | Expected EPS | 0.29 Highest |
ACADIA Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of ACADIA Pharmaceuticals' value are higher than the current market price of the ACADIA Pharmaceuticals stock. In this case, investors may conclude that ACADIA Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and ACADIA Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 20 | 67.27% | 0.0 | 0.198925 | 1.52 |
ACADIA Pharmaceuticals Ownership Allocation
The majority of ACADIA Pharmaceuticals outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in ACADIA Pharmaceuticals to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in ACADIA Pharmaceuticals. Please pay attention to any change in the institutional holdings of ACADIA Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.ACADIA Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 957.8 M. Net Income was 226.45 M with profit before overhead, payroll, taxes, and interest of 617.77 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates ACADIA Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in ACADIA Pharmaceuticals and how it compares across the competition.
About ACADIA Pharmaceuticals Valuation
The stock valuation mechanism determines ACADIA Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of ACADIA Pharmaceuticals. We calculate exposure to ACADIA Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of ACADIA Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1 B | 1.1 B | |
| Pretax Profit Margin | 0.31 | 0.33 | |
| Operating Profit Margin | 0.28 | 0.29 | |
| Net Profit Margin | 0.27 | 0.29 | |
| Gross Profit Margin | 0.82 | 0.86 |
ACADIA Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as ACADIA Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 166.4 M | |
| Quarterly Earnings Growth Y O Y | 1.128 | |
| Forward Price Earnings | 39.6825 |
ACADIA Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of ACADIA Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value ACADIA we look at many different elements of the entity such as ACADIA's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as ACADIA Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use ACADIA Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes ACADIA Pharmaceuticals' worth.Complementary Tools for ACADIA Stock analysis
When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |